title: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
abstract: Fluorescence in situ hybridization (FISH) has become a powerful technique for prognostic assessment in multiple myeloma (MM). However, the existence of associations between cytogenetic abnormalities compels us to re-assess the value of each abnormality. A total of 260 patients with MM at the time of diagnosis, enrolled in the GEM-2000 Spanish transplant protocol, have been analyzed by FISH in order to ascertain the independent influence on myeloma prognosis of IGH translocations, as well as RB and P53 deletions. Survival analyses showed that patients with t(4;14), RB or P53 deletions had a significantly shorter survival than patients without these abnormalities. However, patients with RB deletions without other abnormalities in FISH analysis, displayed a similar outcome to those patients without genetic changes by FISH (46 vs 54 months, P=0.3). In the multivariate analysis the presence of t(4;14), RB deletion associated with other abnormalities, age >60 years, high proportion of S-phase cells and advanced stage of the disease according to the International Staging System retained their independent prognostic influence. In summary, RB deletion as a sole abnormality does not lead to a shortening in the survival of MM patients, whereas t(4;14) confers the worst prognosis in MM patients treated with high-dose chemotherapy.
authors.affiliation: Servicios de Hematología: Hospital Universitario de Salamanca and Centro de Investigación del Cáncer (CIC), Universidad de Salamanca-CSIC, Spain.
authors.forename: N C
authors.initials: NC
authors.lastname: Gutiérrez
authors.forename: M V
authors.initials: MV
authors.lastname: Castellanos
authors.forename: M L
authors.initials: ML
authors.lastname: Martín
authors.forename: M V
authors.initials: MV
authors.lastname: Mateos
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: M
authors.initials: M
authors.lastname: Fernández
authors.forename: D
authors.initials: D
authors.lastname: Carrera
authors.forename: L
authors.initials: L
authors.lastname: Rosiñol
authors.forename: J M
authors.initials: JM
authors.lastname: Ribera
authors.forename: J M
authors.initials: JM
authors.lastname: Ojanguren
authors.forename: L
authors.initials: L
authors.lastname: Palomera
authors.forename: S
authors.initials: S
authors.lastname: Gardella
authors.forename: L
authors.initials: L
authors.lastname: Escoda
authors.forename: J C
authors.initials: JC
authors.lastname: Hernández-Boluda
authors.forename: J L
authors.initials: JL
authors.lastname: Bello
authors.forename: J
authors.initials: J
authors.lastname: de la Rubia
authors.forename: J J
authors.initials: JJ
authors.lastname: Lahuerta
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000328:Adult; D000368:Aged; D002883:Chromosomes, Human, Pair 14; D002894:Chromosomes, Human, Pair 4; D005260:Female; D017353:Gene Deletion; D016161:Genes, Retinoblastoma; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics / Q000628:therapy; D015999:Multivariate Analysis; D011379:Prognosis; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014178:Translocation, Genetic; D014182:Transplantation, Autologous